24,054 Shares in Kenvue Inc. (NYSE:KVUE) Acquired by Atlanta Consulting Group Advisors LLC

Atlanta Consulting Group Advisors LLC acquired a new stake in Kenvue Inc. (NYSE:KVUE) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 24,054 shares of the company’s stock, valued at approximately $556,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Riverview Trust Co bought a new stake in shares of Kenvue during the third quarter valued at approximately $30,000. Ashton Thomas Securities LLC purchased a new position in Kenvue during the 3rd quarter worth $35,000. Studio Investment Management LLC raised its position in Kenvue by 52.1% during the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after purchasing an additional 845 shares in the last quarter. Deseret Mutual Benefit Administrators raised its position in Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after purchasing an additional 651 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of Kenvue in the 2nd quarter worth $61,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.9 %

Kenvue stock opened at $23.82 on Monday. The stock has a 50-day moving average price of $22.77 and a 200 day moving average price of $20.70. The company has a market capitalization of $45.67 billion, a price-to-earnings ratio of 43.31, a price-to-earnings-growth ratio of 2.16 and a beta of 1.36. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.13. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter last year, the company posted $0.31 earnings per share. The firm’s revenue was down .4% compared to the same quarter last year. Sell-side analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be paid a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.44%. Kenvue’s payout ratio is 149.09%.

Analyst Ratings Changes

Several analysts recently weighed in on KVUE shares. Bank of America lifted their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a report on Tuesday, September 24th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. UBS Group boosted their price objective on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Finally, Piper Sandler increased their target price on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and a consensus price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.